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Abstract: The illicit recreational drug of abuse, γ-hydroxybutyrate (GHB) is a potent central nervous 
system depressant and is often encountered during forensic investigations of living and deceased 
persons. The sodium salt of GHB is registered as a therapeutic agent (Xyrem®), approved in some 
countries for the treatment of narcolepsy-associated cataplexy and (Alcover®) is an adjuvant 
medication for detoxification and withdrawal in alcoholics. Trace amounts of GHB are produced 
endogenously (0.5-1.0 mg/L) in various tissues, including the brain, where it functions as both a 
precursor and a metabolite of the major inhibitory neurotransmitter γ-aminobutyric acid (GABA). Available information 
indicates that GHB serves as a neurotransmitter or neuromodulator in the GABAergic system, especially via binding to 
the GABA-B receptor subtype. Although GHB is listed as a controlled substance in many countries abuse still continues, 
owing to the availability of precursor drugs, γ -butyrolactone (GBL) and 1,4-butanediol (BD), which are not regulated. 
After ingestion both GBL and BD are rapidly converted into GHB (t½ ~1 min). The Cmax occurs after 20-40 min and 
GHB is then eliminated from plasma with a half-life of 30-50 min. Only about 1-5% of the dose of GHB is recoverable in 
urine and the window of detection is relatively short (3-10 h). This calls for expeditious sampling when evidence of drug 
use and/or abuse is required in forensic casework. The recreational dose of GHB is not easy to estimate and a 
concentration in plasma of ~100 mg/L produces euphoria and disinhibition, whereas 500 mg/L might cause death from 
cardiorespiratory depression. Effective antidotes to reverse the sedative and intoxicating effects of GHB do not exist. The 
poisoned patients require supportive care, vital signs should be monitored and the airways kept clear in case of emesis. 
After prolonged regular use of GHB tolerance and dependence develop and abrupt cessation of drug use leads to 
unpleasant withdrawal symptoms. There is no evidence-based protocol available to deal with GHB withdrawal, apart from 
administering benzodiazepines. 
Keywords: Analogues, γ-hydroxybutyrate (GBH), intoxication, overdose, pharmacodynamics, pharmacokinetics, treatment, 
withdrawal syndrome. 
INTRODUCTION 
 Among recreational drugs of abuse γ -hydroxybutyrate 
(GHB) is a particularly troublesome substance, because of its 
ready availability, low cost, and risk of adverse interaction 
with other sedative drugs [1-3]. Mortality rates after abuse of 
GHB are high, because there is only a narrow safety margin 
between a recreational dose and a fatal dose, which is only 
5:1 to 8:1 [4-8]. Accordingly, accidental poisoning after 
recreational use of GHB is not uncommon as evidenced by 
admissions to hospital emergency departments for treatment 
[9, 10] and during forensic medical investigations of drug 
intoxication deaths [11-14].  
 GHB emerged as a recreational drug of abuse in the early 
1990s and attracted considerable attention, especially when it 
was implicated in cases of drug facilitated sexual assault 
(DFSA), which is often referred to by the media as “date  
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rape” [15-18]. Known by various slang or street names, such 
as “Easy Lay”, Georgia Home Boy”, “Juice”, “Liquid Ecstasy”, 
"Mils”, “G”, “Liquid X”, “Liquid G” and “Fantasy”, the abuse 
of GHB continues to unfold as evidenced by a continuous 
stream of scientific publications and media reports [19-22].  
 The classification of GHB as a controlled substance in 
USA in 2000 (schedule I) and in EU nations in 2001 
(schedule III or IV) helped to limit its potential for abuse. In 
the UK possession of GHB is illegal and the drug is included 
under Class C of the misuse of drugs legislation. However, 
the organic solvents γ-butyrolactone (GBL) and 1,4-butanediol 
(BD), which are not regulated, are used as alternative sources 
of GHB. Both GBL and BD have cosmetic and industrial 
applications and are therefore not easy to classify as 
controlled substances [10, 23, 24]. These pro-drugs are 
rapidly converted in-vivo into GHB with an absorption half-
life of about 1 min [25]. The pharmacological and behavioral 
effects of GBL and BD stem from their rapid conversion into 
GHB and the latter drug is the main analytical target in 
forensic toxicology [26]. 
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 Pharmacologically, GHB is classified as a central 
nervous system depressant and its mechanism of action 
involves interaction and binding to receptors for the major 
inhibitory neurotransmitter γ-aminobutyric acid (GABA), in 
particular the GABA-B complex [27, 28]. This differs from 
other sedative-hypnotics, such as ethanol, barbiturates and 
benzodiazepines, which work via the GABA-A receptor 
subtype and its chloride ion channel [29, 30].  
 In the form of its sodium salt, GHB is classified as a 
schedule III controlled substance according to US federal 
law. This pharmaceutical product has the proprietary name 
Xyrem® and the generic name is sodium oxybate [31-33]. 
Xyrem® is a medication prescribed to adults suffering from 
narcolepsy-associated cataplexy [34]. Narcolepsy is a 
neurological disorder characterized by excessive daytime 
sleepiness and cataplexy is a brief loss of muscle tone, 
usually in response to emotional arousal or stimuli, such as 
laughter [32]. The patient’s daily dose (4.5 g) of Xyrem® 
should be taken immediately before bedtime and the swift 
absorption and short elimination half-life of GHB ensures 
that next morning insignificant amounts of parent drug 
remain un-metabolized in the blood.  
 In some European nations (e.g. Italy and Austria) the 
sodium salt of GHB (sodium oxybate) is registered as 
Alcover® and made available by Laboratorio Farmaceutico 
C.T. (Sanremo, Italy) for use as pharmacotherapy to support 
alcoholics during detoxification and withdrawal [35, 36]. 
The administration of sodium oxybate seems to be effective 
in maintaining abstinence, with less craving for alcohol and 
lower rates of relapse compared with placebo treatment [37]. 
In contrast to bedtime use of Xyrem® for narcolepsy, 
Alcover® is taken ~4 times daily to alleviate withdrawal 
symptoms and reduce the craving for alcohol [38].  
 The chemical structures of GHB and related compounds 
including its precursors GBL and BD are shown in Table 1 
in comparison with GABA and its metabolites. Another 
name for GHB is 4-hydroxybutyrate, which means that this 
short-chain carboxylic acid has a hydroxyl (-OH) group on 
carbon number four. The close proximity of an alcohol  
(-OH) and a carboxylic acid (-COOH) group within the same 
molecule allows cyclization to the corresponding lactone  
(γ-butyrolactone). This chemical conversion of GHB into 
GBL by intramolecular esterification is utilized when GHB is 
analyzed in blood and urine by GC-FID. The GBL derivative 
shows better solvent extraction and chromatographic properties 
compared with GHB [39].  
 Clinical toxicologists are mainly concerned with acute 
intoxications caused by abuse of GHB and the best way to 
manage and treat the poisoned patient. However, there are no 
effective antidotes that can reverse the sedative effects of a 
GHB overdose. After recreational use of the drug it is not 
uncommon that people take an overdosing and suddenly 
become incapacitated with reduced levels of consciousness, 
which often requires emergency hospital treatment. This 
treatment is essentially supportive because rapid recovery  
is the norm as the drug is metabolized and blood 
concentrations decrease.  
 The quantitative analysis of GHB in blood and other 
body fluids is a relatively simple task and concentrations in 
blood of impaired drivers and intoxication deaths have been 
well documented. Care is needed when GHB concentrations 
in blood and urine samples are interpreted, because small 
amount of the drug is produced endogenously and whether 
the analytical result is indicative of exogenous intake is  
often not easy to answer [40, 41]. The concentrations  
of GHB in blood and urine also seem to increase during 
storage of specimens, which requires use of realistic  
cut-off concentrations to distinguish intake of GHB from 
endogenous or post-sampling synthesis [42].  
 The interpretation of GHB concentrations is more tricky 
when dealing with specimens taken from dead bodies, 
because even higher concentrations are present in blood and 
urine without exposure to GHB during life [43]. Accordingly, 
in post-mortem toxicology higher cut-off concentrations are 
necessary to prevent any false accusations that a person had 
used GHB during the immediate ante-mortem period [44]. 
Much depends on the post-mortem interval, the amount of 
trauma to the body and addition of fluoride ions as an 
enzyme inhibitor and preservative and femoral or cardiac 
blood was taken for analysis [45-47].  
 This article is concerned with the pharmacology and 
toxicology of GHB with main focus on disposition and fate 
in the body, including pharmacokinetic and pharmacodynamic 
aspects. The endogenous concentrations of GHB in blood 
forensic cases including people arrested for driving under the 
influence of drugs (DUID), users of illicit drugs and medical 
examiner poisoning cases. The acute intoxication effects and 
clinical manifestations of GHB overdose are reviewed along 
with diagnosis and treatment of the withdrawal syndrome. 
LITERATURE SEARCH  
 We searched Pubmed and Scopus data bases (from 1970 to 
2014) using key-words γ-hydroxybutyrate; γ-butyrolactone; 
1,4-butanediol; GHB; pharmacokinetics and pharma- 
codynamics of GHB. These key-words were searched alone 
or associated with GHB acute toxicity and GHB withdrawal 
syndrome. Several textbooks, non-indexed sources and 
government websites were also utilized. This search strategy 
Table 1. Chemical structures of GHB and closely related low-
molecular weight compounds. 
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located ~900 items, which were screened to find those 
deemed the most relevant for preparing the current review. 
Accordingly, ~300 articles were scrutinized in more detail 
and the main findings from the studies along with summary 
statistics are presented here. 
 The medical and forensic literature about GHB and its 
analogues is fairly extensive, including a number of fairly 
recent review articles. Worthy of note is a multi-national 
(France, New Zealand, Sweden and UK) review about the 
clinical toxicology of GHB, GBL and BD, which included 
231 literature references [11]. Another newish review dealt 
with pharmacokinetic and pharmacodynamic aspects of GHB 
and included 84 references [13]. A third review focused 
more on acute toxicity and withdrawal syndromes after 
chronic use of GHB, GBL or BD and 124 references were 
cited [48]. A well written review from 2010 dealt with the 
involvement of GHB and its analogs in DFSA cases and the 
associated bibliography listed 164 references [49]. Two 
review articles, one about GHB and the other about BD, 
appeared in the prestigious New England Journal of 
Medicine [50, 51].  
 An important source of information about GHB, GBL 
and BD, as well as other drugs of abuse, comes from the 
reports published by the European Monitoring Center for 
Drugs and Drug Addiction (EMCDDA) in Lisbon, Portugal 
[52]. Their 2008 report on GHB and its precursor GBL 
should be essential reading for those interested in learning 
more about this class of recreational drug [53]. Likewise, the 
role of alcohol and other drugs, including GHB in DFSA 
cases was the subject of a 2008 report from EMCDDA [54]. 
The results showed that sedative-hypnotics were common 
“date-rape” drugs, probably because they make people less 
inhibited and more likely to take risks and after high doses 
they become drowsy and fall asleep. The victims of GHB 
intoxication tend to suffer from anterograde amnesia, making 
it difficult to recall events that precipitated the alleged sexual 
humiliation and abuse.  
 Another government body specializing in harmful effects 
of recreational drugs is the UK’s Advisory Council on the 
Misuse of Dugs (ADMD). This organization produced a well 
organized report about prevalence of GHB in alleged DFSA 
and the relative harmfulness as a recreational drug in society 
[55]. Likewise a joint WHO-EMCDDA report on GHB covered 
all aspects including the history, abuse potential, pharmacology, 
toxicology and dependence and withdrawal syndrome [56].  
 In 2011 the United Nations Office on Drugs and Crime 
(UNODC) produced a report with 204 supporting literature 
citations about the physiology, pharmacology and abuse of 
GHB. This report also contained guidelines for best possible 
sampling and analysis of body fluids in DFSA cases. This 
UN report concluded that ethanol was the psychoactive 
substance most often encountered in blood and/or urine from 
victims of sexual assault, but that use of other drugs also 
deserved consideration, especially when combined with 
ethanol [57]. Because of the short elimination half-life of 
GHB, it is imperative that samples of blood and urine for 
toxicology are obtained soon as possible. The report made 
the following statement [58]. 
“Due to the endogenous nature of GHB, caution must 
be taken in the interpretation of positive findings. 
GHB concentrations have been shown to increase in 
vitro in urine samples during the storage. Therefore, 
the actual recommended cut-off concentration for 
endogenous GHB in urine is 10 mg/L to help to 
distinguish endogenous from exogenous GHB”. 
GHB TRENDS AND CONTEXT OF USE 
 In comparison with many other drugs of abuse, there is 
limited information available regarding trends and patterns 
of GHB use and its diffusion (including GHB analogues) in 
the general population [59, 60].  
 According to a recent EMCDDA report, the prevalence 
of GHB abuse is fairly low in most European nations and 
might be higher in specific areas (e.g. London) and more 
popular among sub-populations, such as those who frequent 
rave parties and gay nightclubs [61]. According to a 2003 
survey by The Independent Drug Monitoring Unit (IDMU) 
abuse of GHB in UK peaked between 1994 and 2002, 
whereas only sporadic use was observed prior to 1994.  
 Because of the low cost of GHB compared with many 
other recreational drugs, adolescents who start to drink alcohol 
excessively switch to taking GHB, because in some respects 
the intoxicating effects are similar, including loss of inhibitions, 
euphoria etc. Table 2 gives a brief summary of the properties 
of ethanol and GHB and the way they act in the body.  
 The average user of GHB is fairly young and many make 
their debut aged 15-22 y, although others start later in life, 
depending on their prior drug history, peer-group influences 
and their economic situation [62]. Among people arrested for 
driving under the influence of GHB in Norway [63] the 
average age of offenders was 28 y (range 21-41), which 
compares with an average age of 26 y (range 15-50 y) in 
Sweden [64].  
 The US National Institute of Drug Abuse (NIDA) sponsored 
a questionnaire survey to investigate prevalence of drug abuse 
throughout the 50 US states. Their 2013 report “Monitoring 
the Future” was recently released and part 1 dealt with 
secondary school students and part 2 college students and 
adults aged 19-50 y [65, 66]. In these reports, GHB is 
considered a “club drug” along with ketamine and rohypnol. 
The annual prevalence of GHB use was given as 1% and 
since 2000, the year when GHB was declared illegal, a 
steady decline in the consumption of this illegal drug by 
adolescents and young adults was noticed. 
 For a long time GHB as sodium oxybate was considered 
an orphan drug, although has now been registered as a 
pharmaceutical product and given the proprietary name 
Xyrem® (Jass Pharmaceuticals, Palo Alto, CA). The medication 
is used to treat cataplexy, which is an important symptom in 
the disease complex narcolepsy. This legitimate use of GHB 
raises a concern about the possible diversion of Xyrem® 
from a patient population to illicit use in a similar way to 
opioids, such as methadone.  
 Another therapeutic use of GHB (sodium oxybate, 
Alcover®) is adjunctive therapy for treating the alcohol 
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withdrawal syndrome. This application of GHB was recently 
reviewed and found to be just as effective as diazepam or 
chlormethiazole in alleviating initial withdrawal symptoms 
and also as effective as naltrexone or disulfiram (Antabuse®) 
in maintaining abstinence and preventing relapse [36]. 
However, GHB is not recommended for certain patient 
groups, such as poly-drug users and those co-addicted or 
recovering from cocaine or heroin abuse.  
 Sometimes referred to as a ”club-drug” GHB became 
popular among young people attending nightclubs and rave 
parties in various countries, such as Australia, Holland, UK, 
and USA [24, 67]. Suggestions have been made that GHB 
might have some therapeutic potential for the treatment of 
depression and anxiety in certain patient categories, although 
this remains controversial considering the drug’s high abuse 
potential [68].  
HISTORY OF GHB 
 The Russian chemist Alexander Saytzeff (1841-1910) 
synthesized GBL in 1874 by the reduction of succinyl 
chloride as was described in Liebigs Ann Chem“Ueber die 
reduction des succinylchlorids” [69]. The modern period of 
interest in GHB research began in the 1960s when the French 
physician Dr. Henri Laborit (1914-1995), of chlorpromazine 
fame, took an interest in studying the physiological effects  
of GHB. He noticed that GHB was a structural analogue of 
GABA, and unlike the latter was orally active and crossed 
the blood-brain barrier and therefore wondered if this might 
furnish an indirect way to increase GABA levels in the brain 
[41]. 
 GHB is a structural isomer of β-hydroxybutyrate (BHB), 
the major ketone body, which is generated in excess during 
food deprivation and starvation. BHB provides an alternative 
fuel for the brain when glucose is lacking and glycogen 
stores are depleted [70]. This raises interesting questions 
about the respective roles of BHB and GHB on brain chemistry 
and functioning in man and animals during ketosis.  
 The experiments of Laborit demonstrated that GHB was 
a potent pharmacological agent and high doses resulted in 
deep sedation and sleep. This created an interest in the use of 
GHB as an intravenous anesthetic, because it had minimal 
cardiovascular and respiratory depression effects and the 
liver and the kidney function appeared normal. However, the 
clinical trials with GHB were disappointing because the drug 
possessed insufficient analgesic effect and the proper dose 
was difficult to judge and control. Some patients vomited 
and other suffered from convulsions, so medical testing of 
GHB in anesthesiology was abandoned in favor of much 
safer intravenous anesthetic agents (e.g ketamine, propofol). 
Nevertheless, GHB was registered in Germany for use as 
intravenous anesthetic (Somsanit®) requiring doses of 60-80 
mg/kg body weight [71]. 
 The relationship between plasma concentrations of GHB 
and state of consciousness after intravenous administration 
was reported in 1964 the results of which are summarized in 
Table 3 [72].  
 During the 1970-1980s GHB became popular as a dietary 
supplement and could be purchased over the counter at 
health-food stores. The product became popular with dieters 
and body-builders who believed that it helped them burn fat 
and build muscle and also stimulated the production of 
growth hormone. The use and abuse of GHB spread to other 
groups of individuals in society and reports began to describe 
its use in criminal activity and many people overdoses and 
needed emergency medical treatment. 
Table 2. Some characteristic properties of GHB compared with ethanol two recreational drugs often ingested together.  
Property Ethanol (EtOH) γ-Hydroxybutyrate (GHB) 
CAS-number1 64-17-5 591-81-1 
Empirical formula C2H6O C4H8O3 
Structural formula  OHCH3  
 O
OH
OH
 
Molecular weight g/mol  46.07 104.1 
pKa 15.9 4.7 
Sodium (Na) salt Na ethoxide Na oxybate2 
Plasma-protein binding None None 
Plasma/blood ratio 1.15-1.25:1 1.15-1.25:1 
Water solubility Mixes completely Mixes completely 
Endogenous blood and urine concentrations  ~0.5-1 mg/L ~0.5-1 mg/L 
Fatal blood conc.  >4000 mg/L >500 mg/L 
Site of action in brain GABA-A receptor via the chloride ion channel GABA-B receptor via G-protein coupling  
1Chemical Abstract Registry number. 2Registered in some countries as Xyrem® 
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 Throughout the 1980s and 1990s, GHB gained a reputation 
of being able to enhance their sex-drive and libido, which 
made it popular among people frequenting gay clubs and 
rave parties. After the right dose, people become more 
talkative and physically active, some experienced euphoria, 
had less inhibitions, which prompted them to take risks 
including multiple sex partners [67].  
 More serious from a forensic and legal standpoint was 
the growing number of reports that GHB and its analogs 
were used to spike a person’s drink causing incapacitation so 
a perpetrator could engage in non-consensual sex [17, 73, 
74]. However, obtaining unequivocal evidence that GHB 
was in fact used for this purpose was a challenge, owing to 
the rapid metabolism and clearance from the body [49]. The 
rapid elimination of GHB meant that waiting too long after 
the crime was committed concentrations of GHB were close 
to the endogenous levels.  
 Nevertheless, the considerable media attention given to 
illicit use of GHB and its potential as a “date-rape” drug 
motivated the US Food and Drug Administration (FDA) to 
make GHB a controlled substance Schedule I (March 2000). 
However, because there are also legitimate medical uses for 
GHB, such for cataplexy attacks in patients with narcolepsy, 
in the form of sodium oxybate GHB was placed in schedule 
III as Xyrem®. According to the UK Misuse of Drugs  
Act in 2001 GHB was placed in schedule IV. The 1971 UN 
convention on psychotropic substances also classified GHB, 
thus making it a controlled substance in all EU nations.  
ANALYTICAL METHODS 
 The methods currently available for screening and 
quantitative analysis of GHB in biological specimens were 
recently the subject of a comprehensive review with 128 
references [39]. The authors documented a wide variety of 
analytical methods for determination of GHB in urine and 
blood as well as other biological specimens. These alternative 
specimens included saliva [75], vitreous humor [76-78], 
blood spots [79, 80] and hair strands [81-84].  
 For forensic purposes, the analytical approach 
recommended involves gas chromatography (GC) coupled 
with a flame ionization detector (FID), or better still a mass 
detector (MS) [85]. Use of GC-MS to analyze GHB means 
that deuterium labeled d6-GHB can be used as an internal 
standard after making the trimethylsilyl (TMS) derivative 
[86, 87]. Several liquid chromatography-mass spectrometry 
methods (LC-MS) are described for analysis of GHB and 
such technology is becoming used more and more in forensic 
laboratories [88-90].  
 The analytical “gold standard” method recommended for 
forensic purposes involves GC-MS or LC-MS or hybrid 
technology GC-MS/MS or LS-MS/MS [91-93]. These 
procedures are highly sensitive, accurate, precise and 
specific for their intended purposes. Use of high resolution 
GC-MS or LC-MS/MS have become the norm in clinical and 
forensic laboratories worldwide along with liquid chromato- 
graphy time of flight (TOF) mass spectrometry (LC-TOF-
MS) and identification by accurate mass. Such technology is 
proving extremely useful for making a rapid screening and 
verification analysis of licit and illicit drugs in toxicological 
specimens [89, 94].  
 The review of analytical methods cited above endorsed 
the simpler GC-FID method after conversion of GHB into 
GBL at acidic pH and then quantitative chromatographic 
analysis of the more volatile GBL [39]. Preparation of the 
GBL derivative has the advantage of easier extraction into 
organic solvents and better chromatographic separation 
properties with sharp peaks and good linearity over a wide 
concentration range of 5-1000 mg/L [95]. 
 A validated procedure that permitted simultaneous 
analysis of toxic glycols and GHB in plasma and urine by 
GC-MS was described [96]. The possibility to screen for 
multi-toxins in a single run is especially useful in clinical 
toxicology and emergency medicine. Another recent article 
described a method to determine GHB, GBL, BHB, BD as 
well as pregablin together in the same sample by a highly 
sensitive and specific UPLC-MS-MS method [88]. 
 A number of simpler and more economical enzymatic 
methods are available for the analysis of GHB in biological 
fluids [97, 98]. One of these involves oxidation with the 
enzyme GHB dehydrogenase and the co-factor NAD+ which 
becomes reduced to NADH, and the later is determined 
quantitatively by UV spectrometry at 340 nM [99].  
 A recent photometric procedure was adapted to work 
with a Thermo Scientific MGC-240 auto-analyzer and this 
furnished a rapid method for determination of GHB in blood, 
vitreous humor and urine [97]. The authors reported a good 
correlation when paired samples were analyzed with a more 
specific GC-MS method. They recommended making an 
Table 3. Relationship between plasma concentrations of GHB and state of consciousness after intravenous adminsitration.  
N = 16 patients received 50-115 mg/kg of GHB and afterwards the hypnotic effect was observed for 20-300 min post-
dosing [72]. 
Mean (Range) of GHB Concentration, mg/L Clinical Observations/Hypnotic Effects1  
311 (244-395) Deep sleep (no response to stimuli) 
224 (151-293) Medium sleep (blinking) 
135 (63-162) Light sleep (occasioanl eye opening) 
47 (0-99) Awake 
1The clinical effects lagged behind the peak plasma concentration. 
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initial screening by the enzyme method and then verification 
of all positives by LC-MS or GC-MS. 
 In forensic toxicology casework, a good laboratory practice 
is to identify drugs and metabolites in more than one bio-
fluid as definite proof of intake, such as when GHB-related 
deaths or DFSA cases are investigated. The presence and 
concentration of GHB in urine is of particular interest 
because this reflects the concentrations in blood during the 
time urine was produced in the kidney and stored in the 
bladder before voiding. In post-mortem toxicology if GHB is 
verified positive in urine but is below the analytical cut-off 
concentrations in blood, this can be interpreted as evidence 
of exogenous intake.  
 The verification of a parent drug and its main metabolite 
in blood or other biological material also strengthens the 
conclusion of exogenous intake. In this connection, GHB 
was recently identified in urine conjugated with glucuronic 
acid [100]. The concentrations of urinary GHB-glucuronide 
ranged from 0.11 to 5 mg/L (mean 1.3 mg/L, N = 50). In the 
same way that ethyl glucuronide is widely used as a biomarker 
of ethanol exposure, in the future it might be possible to utilize 
GHB-glucuronide as marker of GHB exposure [101, 102].  
PHARMACODYNAMICS OF GHB 
 Fig. 1 shows the biosynthesis and metabolism of 
endogenous GHB along with formation from its exogenous 
precursors GBL and BD. GHB interferes with GABAergic 
neurotransmission and this drug can be considered a GABA-
B agonist [103, 104]. The neurons that release GABA are 
mostly localized in the hippocampus, cortex and amygdala. 
GHB receptors are located in these sites, in pre- and post-
synaptic cells and shows high affinity for these G-protein 
coupled receptors [105-108].  
 Unlike most other CNS depressants (e.g. ethanol, ben- 
zodiazepines) that work via the GABA-A receptor complex 
to dampen neuronal activity, GHB exerts most of its effects 
through binding to the GABA-B receptor complex [108, 
109]. However, endogenous levels of GHB in the brain are 
too low to permit any agonist activity [106, 110]. The effects 
of GHB are mediated predominantly by interaction with 
GABA-B receptors [111], although some older animal 
studies implicate also dopamine and serotonin neuro- 
transmission [112]. GHB initially acts as an inhibitor of 
dopamine release, although depending on the dose turnover 
of dopamine is later increased [113]. The involvement of 
glutamate receptors (NMDA) was also thought to explain 
GHB-induced cataplexy in animal studies [114]. The 
existence of high affinity receptor binding sites for GHB 
distinct from GABA-B has been postulated to explain some 
of the pharmacological effects produced by this depressant 
drug [115, 116].  
 The onset of GHB's effects on performance and behavior 
occurs 15-30 min after ingestion and lasts for up to 1-6 hours 
depending on the dose. The dose-effect curve for GHB is 
 
Fig. (1). Metabolic inter-relationships between GHB and its precursors GBL and BD and the biosynthesis and degradation of the inhibitory 
neurotransmitter GABA. 
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rather steep, which means that small increases in dose cause 
disproportionate increases in behavioral effects and toxicity. 
For recreational purposes, GHB doses of 1-2 gram are often 
sufficient to produce feelings of euphoria and well being, but 
after larger doses people tend to become drowsy and as 
concentrations of GHB in blood increase above 100 mg/L 
there is marked effects on speech and motor coordination. 
Also important for the effects of GHB is the route of 
administration and whether other depressants were co-
ingested and the development of tolerance. 
 After two healthy volunteers consumed 1.5 mL GBL, 
they experienced mild central nervous effects after 15 min, 
but these subsided completely 30 min later [117]. There is a 
low margin of safety between a recreational dose and a fatal 
dose because blood concentrations of 80-100 mg/L causes 
inebriation whereas 300-500 mg/L might result in death from 
respiratory depression and circulatory collapse.  
PHARMACOKINETICS OF GHB 
 Information about the disposition and fate of GHB in the 
body has been obtained from several controlled human dosing 
studies covering a range from 12.5-50 mg/kg body weight, 
usually as sodium oxybate. The general conclusions from 
these pharmacokinetic studies are summarized in Table 4.  
 Three important pharmacokinetic (PK) parameters are 
Cmax, tmax and t½ and can be derived from the concentration-
time profiles. The most recent pharmacokinetic study involved 
an oral dose of 25 mg/kg and was published in 2012 [118]. 
Table 5 presents values for Cmax, tmax and t½ from all 
relevant PK studies of GHB. The overall findings are clear-
cut, namely GHB is rapidly absorbed from the gut and also 
rapidly eliminated from the body with a t½ of 30-50 min. This 
means that after 150-250 min (5 x t½) the concentrations  
of GHB in plasma are barely measurable and hence the 
description fast-in and fast-out [119].  
 In most pharmacokinetic studies the concentrations of 
GHB are determined in plasma or serum and not in whole 
blood. The GHB concentrations in serum are expected to be 
higher than in blood in a similar way as ethanol distribution 
[120]. Both drugs are completely miscible with water, there 
is no binding to plasma proteins so the water content of 
plasma and erythrocytes is a deciding factor for serum/blood 
distribution ratios [121].  
 The pharmacokinetics of GABA appears to be dose-
dependent and the metabolizing enzymes become saturated 
with substrate after massive (abuse) doses are taken and high 
concentrations are reached in plasma. After smaller 
recreational doses when Cmax in plasma is below 100 mg/L, 
first-order kinetics is an appropriate model to describe the 
post-absorptive phase of the C-T profile [122]. After large 
doses of GHB or its precursors when the hepatic enzymes 
are saturated the initial descending phase of the C-T profile 
is best described by zero-order kinetics [123].  
 The dose-dependent non-linear kinetics of GHB suggests 
that C-T profiles might be best described by the Michaelis-
Menten equation [124]. This model would yield values of 
km and Vmax that are characteristic of substrate and the 
plasma concentration reached. When the concentration of 
GHB is more than double km the metabolizing enzymes are 
approaching saturation and zero-order kinetics applies. For 
drugs eliminated by non-linear kinetics the C-T profile 
spanning from high to low concentration looks more like a 
hockey stick rather than a straight line (zero-order slope) or a 
pure exponential decay function (first-order kinetics). 
 Examples of concentration-time profiles of GHB for 
health men (N = 18) and women (N = 18) after an oral dose 
of 4.5 g as sodium oxybate are shown in Fig. 2 [125]. The 
drug was rapidly absorbed in both sexes and for the first 1-2 h 
after passing the peak it appears that that rate of elimination 
occurs at a constant rate per unit time. As the concentrations 
Table 4. Summary of the disposition of GHB in the body administered as Xyrem® (sodium oxybate) based on the results from a 
large number of controlled human dosing studies. 
Pharmacokinetic Property or 
Characteristic of GHB 
Findings from Controlled Human Dosing Studies Ranging from 12.5 to 72 mg/kg GHB 
Absorption and bioavailability Rapidly absorbed after oral administration, tmax was reached 20-40 min although oral bioavailability is only 25-40% .1  
Dose-proportionality Non-linear kinetics, doubling the dose from 4.5 to 9.0 g increased area under the curve 3.8 fold and Cmax was 
increased 2.4-2.9 times. 
Distribution Distributes into total body water with a Vd ranging from 0.19-0.38 L/kg and negligible amounts of drug (<1%) bind to 
plasma proteins. 
Metabolism Approximately 95-98% of dose is metabolized in the liver to end products carbon dioxide and water, via the Krebs 
cycle, and there are no active metabolites. 
Plasma elimination kinetics Dose dependent pharmacokinetics after high (toxic) doses enzymes are saturated with substrate and zero-order 
kinetics operates. After low therapeutic doses GHB is eliminated with a terminal plasma t½ of 30-50 min.  
Excretion Approximately 1-2% (<5%) of the dose is excreted unchanged in the urine. 
Accumulation and enzyme 
induction 
After repeated nightly doses of sodium oxybate (4.5 g) for 8 weeks, there was no accumulation of GHB in plasma and 
t½ was about the same for the first dose (43 min) and the 56th dose (46 min).  
1Depends on fed or fasting state. 
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of GHB in plasma decreases, there is a change in shape of 
the C-T profile towards an exponential function and first-
order kinetic processes and t½ best describe the elimination 
from the body.  
 The overall shape of C-T profiles of GHB for men and 
women are therefore very similar with a median time to peak 
of 1 h and Cmax of 88 mg/L (men) and 83 mg/L (women) 
[125]. The elimination half-life of GHB did not depend on 
gender, being 0.65 ± 0.23 h (men) and 0.61 ± 0.12 h (women). 
The area under the curve (AUC) was slightly greater in men 
(241 mg x h/L) than in women (233 mg x h/L).  
 Other studies have reported pharmacokinetic profiles of 
GHB in sober alcoholics [35], in patients with liver 
dysfunction [126] and in people suffering from narcolepsy 
[127] and the findings are not much different from healthy 
controls, rapid absorption, early occurring tmax and short 
plasma elimination half-life.  
 In a chronic dosing study, the pharmacokinetic profile of 
GHB (sodium oxybate) was studied in patients suffering 
from narcolepsy before and after 8 consecutive weeks of 
drug treatment (4.5 g before bedtime). The mean peak GHB 
concentration was higher after 8 weeks of treatment (p<0.05) 
with a Cmax of 104 ± 31 mg/L compared with 90 ± 31 mg/L 
for the first dose [128]. However this study gave no evidence 
of drug accumulation in plasma after multiple daily doses 
and both tmax and t½ were about the same after the first and 
last dose of GHB.  
 Similar conclusions were reached regarding lack of 
accumulation when GHB when alcohol-dependent patients 
received 25 mg/kg GHB daily every 12 h for 7 consecutive 
days [35]. The results of these chronic dosing studies also 
speak against the notion of induction of GHB metabolizing 
enzymes, principally cytosolic GHB dehydrogenase. 
ABSORPTION 
 A low molecular weight, the high solubility in water and 
the lack of binding to plasma proteins means that GHB is 
rapidly absorbed from the gut and peak concentration in 
plasma are reached by 20-40 min post-ingestion. However, 
oral bioavailability of GHB is fairly low corresponding  
to 25-40% according to some authorities with a major 
influence of taking the drug on an empty stomach or after 
eating a meal.  
Table 5. Summary of pharmacokinetic parameters Cmax, tmax and t½ for GHB derived from controlled human dosing studies in 
which GHB was administered as its sodium salt (sodium oxybate). Concentration-time curves of GHB were constructed 
from analysis of plasma or serum and not whole blood. 
Study [Reference] Year Dose N1 Cmax, mg/L Mean/Median Tmax, Min Mean/Median Elimination Half-Life t½ Min 
Abanades et al [122] 2006  40 mg/kg 
50 mg/kg 
60 mg/kg 
72 mg/kg 
8 
8 
8 
8 
79 
83 
114 
130 
42 
36 
36 
54 
44 
43 
40 
34 
Abanades et al [130] 2007  50 mg/kg 5 83  36 43 
Borgen et al [125] 2003  4.5 g 18 
18 
34 
34 
88 (men) 
83 (women) 
142 (fasted) 
60 (fed)2 
60  
60  
45  
1202  
39 
37 
34 
412 
Borgen et al [128] 2004  4.5 g 13 90 
1043 
52 
433 
43 
463 
Brenneisen et al [132] 2004  25 mg/kg 8 40  41 30 
Ferrara et al [35] 1992  25 mg/kg 10 54 
554 
30  
304  
27 
264 
Ferrara et al [126] 1996  25 mg/kg 85 
86 
68 
47 
45  
45  
32 
56 
Palatini et al [124] 1993 12.5 mg/kg 
25 mg/kg 
50 mg/kg 
8 23 
46 
80 
25  
30  
45  
20 
22 
23 
Thai et al [131] 2006  50 mg/kg 16 73 
847 
57 
547 
52 
677 
Scharf et al [127] 1998  3.0 g 6 63 40 53 
Brailsford et al [118] 2012  25 mg/kg 12 59 23 32 
1Number of subjects. 2After a high fat meal. 3After nightly treatment with GHB for 8 weeks in patients suffering from narcolepsy. 4After 13 daily doses of GHB to alcohol dependent 
patients. 5Cirrhotic patients without ascites. 6Cirrhotic patients with ascites. 7Together with 0.6 g/kg ethanol. 
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 One of the first controlled dosing studies of GHB 
pharmacokinetics originated from Italy because sodium 
oxybate was being used in that country in clinical medicine 
for alcohol withdrawal. Eight healthy male volunteers 
participated in a randomized cross-over design experiment 
and received increasing oral doses of 12.5, 25 and 50 mg/kg 
[124]. The tmax of GHB increased with increasing dosage 
(25, 30 and 45 min, respectively) with a range from 20 to 60 
min. Likewise, Cmax also increased in relation to dose 23 
mg/L (12.5 mg/kg), 46 mg/L (25 mg/kg) and 92 mg/L (50 
mg/kg). The plasma elimination t½ was 20 min, 22 min or 
23 min and thus independent of dose despite a four-fold 
variation (12.5 to 50 mg/kg), which fits with the assumption 
of first-order elimination kinetics.  
 This Italian study concluded that both oral absorption and 
elimination kinetics of GHB were capacity limited and that 
AUC increased disproportionally with dose. The existence of 
non-linear kinetic meant that doubling the dose from 4.5 to 
9.0 g increased the AUC 3.8 fold and Cmax 2.4-2.9 fold.  
 A more recent study of GHB pharmacokinetics involved 
12 healthy volunteers (6 males and 6 females) and a dose of 
25 mg/kg given as sodium oxybate. The study was 
particularly impressive because of a good experimental 
design, use of a highly reliable method of analysis and taking 
an adequate number of blood samples so that C-T profiles 
could be plotted unequivocally. The absorption of GHB was 
rapid with Cmax occurring after 24.6 min at a concentration 
of 59.4 ± 10.2 mg/L [118].  
 As with many other drugs, the concomitant intake of 
food delays the rate of absorption after oral intake and in the 
case of GHB this effect was rather dramatic as shown in  
Fig. 3. After a dose of 4.5 g sodium oxybate the Cmax was 
60.1 mg/L (n = 34) after subjects had eaten a fat-rich meal 
compared with 142 mg/L (N = 34) when the drug was taken 
on an empty stomach. The median tmax was increased from 
45 min to 120 min in the fed state, whereas t½ was not much 
influence by the postprandial state [125]. 
DISTRIBUTION 
 The distribution of GHB in the body fluids and tissues 
depends on the distribution of total body water because there 
is negligible binding of the drug to plasma proteins. 
According to several studies, the volume of distribution (Vd) 
of GHB in healthy subjects ranges from 0.19 to 0.33 L/kg, 
although higher values have also been found. In patients 
suffering from narcolepsy or liver failure the Vd was not 
much different (0.23-0.32 L/kg) from healthy controls.  
 The speed and extent of distribution of GHB from the 
bloodstream to tissue compartments depends on water 
content and ratio of blood flow to tissue mass. Since GHB 
distributes into total body water, this suggests that Vd should 
be lower in females compared with males, although this has 
not been verified by experiment. Furthermore, Vd for GHB 
should be lower in the elderly and in obesity, owing to less 
water per kg body weight in these individuals.  
SERUM/BLOOD CONCENTRATION RATIO  
 During pharmacokinetics of GHB the C-T profiles were 
plotted from results of analyzing near simultaneous samples 
of serum and blood [118]. The 12 volunteers (6 men and  
6 women) ingested a dose of 25 mg/kg GHB as sodium 
oxybate and a reliable GC-MS method with d6-GHB as 
internal standard was used for analysis. 
 The concentrations of GHB in serum were always higher 
than in whole blood, as expected from differences in water 
content of the specimens as shown by the plots in Fig. 4 
[118]. 
 The mean Cmax (± SD) for GHB in serum was 59.4 ± 
10.2 mg/L (N = 12) compared with Cmax of 48.8 ± 8.8 mg/L 
in whole blood (N = 12). Thus the mean serum/blood ratio of 
GHB is 1.23:1 under these conditions and stands in good 
agreement with the water content of serum (~92-94%) and 
blood (~78-80%). There were no gender differences in the 
distribution of GHB between serum and blood.  
 
Fig. (2). Plasma concentration-time profiles of GHB after a single 
oral dose of 4.5 g sodium oxybate in healthy adult males (n = 18) 
and females (N = 18). The graph was redrawn from reference [125]. 
 
Fig. (3). Plasma concentration-time profiles of GHB in healthy 
adult females (N = 34) following a single oral dose of 4.5 g sodium 
oxybate after a fat-rich meal or after an overnight fast. The graph 
was redrawn from reference [125]. 
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 After two male volunteers ingestion of a single dose of 
GBL (1.5 mL), the concentrations of GHB were determined 
in serum and blood by a liquid chromatography tandem mass 
spectrometric (LC-MS/MS) method. The Cmax in serum 
(blood) were 95 mg/L (58 mg/L) for the first subject and 106 
mg/L (83 mg/L) for the second person, giving serum-to-
blood distribution ratios of 1.63 and 1.28:1, respectively. 
With an analytical detection limit of 1 mg/L, the detection 
window of GHB in serum was 4-5 h compared with 8-10 h 
for the analysis of urine. 
 Animal studies have been performed to test the 
distribution of GHB between plasma and erythrocytes in 
whole blood and the mean plasma/blood concentration ratio 
was 1.33 (N = 74), being in good agreement with the human 
studies [129]. 
METABOLISM  
 The bulk of the dose of GHB administered (95-98%) 
undergoes hepatic metabolism by a series of enzymatic 
pathways (Fig. 1). A major route of metabolism is oxidation 
by GHB dehydrogenase to give succinic semialdehyde, by 
which further oxidation is converted into succinic acid, 
entering the intermediary metabolism and via the Krebs 
cycle transformed into end-products carbon dioxide and 
water.  
 The biosynthesis and metabolism of GHB is also closely 
linked to GABA metabolism and GHB can be considered 
both a metabolite and a precursor of GABA. The amino  
acid glutamate passes the blood-brain barrier and is 
decarboxylated to produce GABA. Metabolism of GABA is 
accomplished by an aminotransferase enzyme to give 
succinic semialdehyde, which can either become oxidized to 
give succinic acid or alternatively reduced to form GHB.  
 Whatever the exact metabolic pathways involved, most 
published studies verify that the terminal plasma elimination 
half-life for GHB in humans ranges from 30-50 min. There 
is no evidence that the metabolic enzymes that clear GHB 
from the blood are boosted after chronic exposure to 
substrate.  
EXCRETION 
 Only a small fraction of ingested GHB (~2-5%) is 
excreted unchanged in the urine according to several human 
dosing and recovery studies.  
 Urine voids were collected from 12 volunteers (6 men 
and 6 women) for up to 12 hours after they had received a 
GHB dose of 25 mg/kg dosing [118]. In 11 of 12 subjects, 
the tmax in urine was reached after 1 h and the urinary Cmax 
ranged from 32.6 to 161.3 mg/L (mean 67.3 mg/L). Urinary 
concentrations decreased fairly and rapidly thereafter in all 
subjects and were below 10 mg/L, a commonly used cut-off 
concentration, 4 hours post-dosing. The results confirmed 
that 0.6-2.5% (mean 1.3%) of the administered dose  
(25 mg/kg) was excreted in urine [118].  
 Abanadas et al [130] recovered <2% of the dose of GHB 
(50 mg/kg), whereas Thai et al [131] found between 4-5 % of 
the dose of 50 mg/kg GHB in urine. In one of these studies 
GHB was administered together with ethanol (0.6 g/kg), 
although the excretion characteristics of GHB were unchanged. 
Seemingly any diuresis caused by consumption of ethanol 
was unimportant for the urinary excretion pattern of GHB. 
Other studies gave quantitative results for GHB excretion in 
urine as 0.2-2.1% of a dose of 25 mg/kg and a mean of 1.2% 
[132]. Another study showed that the window of detection of 
GHB from analysis of urine was < 10 h and that 0.6-1.16% 
of the dose was recoverable [133]. 
 All the above results confirm that ~2-5% of the dose was 
recoverable in urine samples as GHB and that the window of 
detection was fairly short. This reinforces the need to be 
prompt and expeditious when sampling blood and urine in 
forensic cases to maximize the change of verifying 
exogenous intake of GHB [58]. If more than 10-12 hours 
have elapsed after the alleged attack there is little hope of 
detecting and measurable amounts of GHB as evidence in 
DFSA and other criminal cases.  
GHB-ETHANOL INTERACTIONS  
 Because GHB is often abused or taken by people 
consuming ethanol, this raises the possibility of an adverse 
interaction between these two sedative drugs. This question 
was studied in a double-blind placebo controlled cross-over 
design involving 16 health volunteers [131]. They drank 
ethanol 0.6 g/kg with or without GHB (50 mg/kg). The 
resulting mean C-T profiles of GHB in the two arms of the 
study are shown in Fig. 5. 
 In one study, the co-ingestion of ethanol resulted in a 
16% higher plasma Cmax for GHB (84 vs 73 mg/L), 
whereas tmax remained about the same (54 vs 57 min). The 
plasma elimination half-life was 29% longer (67 vs 52 min) 
after the co-ingested ethanol although these differences in 
pharmacokinetic parameters were not statistically significant 
(p>0.05). Neither were the C-T profiles of ethanol influenced 
by the presence of GHB in blood (Fig. 6).  
 
Fig. (4). Serum and whole-blood concentration-time profiles of 
GHB after a single oral dose of 25 mg/kg as sodium oxybate in 12 
healthy volunteer (6 men and 6 women). The dashed horizontal line 
at a GHB concentration of 5 mg/L represents the analytical reporting 
limit. The graph was redrawn from reference [118]. 
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 In the GHB + ethanol arm of the study subjects reported 
experiencing more adverse effects and two subjects suffered 
from hypotension and six had episodes of vomiting [131]. In 
the same study, the window of detection of GHB in urine 
was investigated using the widely used cut-off concentration 
of 10 mg/L. The results showed that 12.5% of samples 
collected from 3-6 h, 81.3% of samples voided from 6-12 h 
and 100% of samples from 12-24 h would have been reported 
as negative for GHB at a threshold of 10 mg/L. 
 The interaction between ethanol and GHB has also been 
studied in various animal models, such as rats and baboons 
[134]. The combined influences of ethanol and GHB 
prolonged sleep time without having any influence on the 
pharmacokinetics of either GHB or ethanol.  
METABOLIC CONVERSION OF BD TO GHB  
 Both GBL and BD are rapidly converted in the body into 
GHB and because these pro-drugs are not classified as 
controlled substances, they represent a more easily available 
and legal source of GHB [117, 135, 136].  
 An example of the rapid and extensive conversion of BD 
into GHB is seen in the graphs drawn in Fig. 7 showing 
mean C-T profiles in 8 healthy volunteer after a dose of 25 
mg/kg 1.4-butanediol was taken mixed with orange or 
cranberry juice [135]. The maximum plasma concentration 
of GHB was 45.6 ± 19.7 mg/L and occurred at 39.4 ± 11.2 
min after ingestion of BD. The average t½ of GHB derived 
from BD was 32.3 ± 6.6 min in good agreement with results 
when 25 mg/kg GHB was administered.  
ENDOGENOUS CONCENTRATIONS OF GHB 
 Trace amounts of GHB are present in body fluids and 
tissues from healthy individuals never exposed to GHB. 
Hence GHB is a normal endogenous product of metabolism, 
presumably formed via GABA or the even endogenous 
presence of GBL or BD. Using reliable analytical methods, 
most investigators report endogenous urinary GHB 
concentration in the range 0.5-2 mg/L with some outliers as 
high as 5 mg/L [137, 138].  
 The range of endogenous GHB concentrations in N = 670 
urines donated by people never exposed to GHB were 0.34 
mg/L to 5.7 mg/L (median 3.0 mg/L). Similarly, in N = 240 
blood samples the endogenous GHB concentration ranged 
from 0.17 mg/L to 1.51 mg/L (median 0.8 mg/L) [138]. 
These results were used to support threshold concentrations 
for reporting of 5 mg/L for blood and 10 mg/L for urine. 
However, concentrations of GHB in urine tend to increase 
after voiding and during storage of specimens at elevated 
temperatures, which also needs consideration [43, 139].  
 
Fig. (5). Plasma concentration-time profiles of GHB alone (50 mg/kg 
as Xyrem) compared with the same dose taken 15 min after the 
subjects drank a moderate dose of ethanol (0.6 g/kg). Mean curves 
for N = 16 subjects are plotted. The graph was redrawn from 
reference [131]. 
 
 
Fig. (6). Plasma concentration-time profiles of ethanol after 0.6 g/kg 
with or without co-ingestion of GHB (50 mg/kg Xyrem). Mean 
curves for N = 16 subjects based on data from reference [131]. 
 
Fig. (7). Plasma concentration-time profiles of GHB in 8 volunteers 
after they ingested 1,4-butanediol (25 mg/kg) in orange juice. The 
graph was redrawn from reference [135]. 
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 A toxicologist has to distinguish endogenous GHB from 
exogenous intake and therefore practical cut-off limits must 
be established [44]. The unequivocal identification of GHB 
in biological specimens from living and deceased persons is 
not a problem, the trick is to be able to state with certainty 
that the person ingested an illicit drug [84, 140]. There 
represents a difficult balance the dangers of reporting a  
false-positive or false-negative result of GHB analysis in 
forensic casework. The benefit of the doubt in criminal cases 
should be given to the suspect, which speaks towards use of 
conservative cut-off concentrations.  
 The endogenous concentrations of GHB are higher in 
urine than in blood when the samples are obtained from 
living subjects, although the opposite holds for autopsy 
specimens. This requires different urinary and blood cut-off 
concentrations depending on whether analytical results refer 
to living or deceased persons [141-143]. Other factors of 
importance for the stability of GHB include urinary tract 
infections, duration and temperature of storage and whether 
any sodium fluoride was as present as an enzyme inhibitor 
and preservative [45].  
 Urines samples were voided by 1126 healthy female 
subjects and endogenous GHB concentrations were determined 
by a GC-MS method. The mean concentration of GHB was 
0.84 mg/L (median 0.68 mg/L) with an overall range from  
0-5.5 mg/L [144]. These concentrations did not seem to 
depend on urinary pH, the person’s body mass index (BMI) 
nor the donor’s racial origin. A weak correlation (R2 = 0.3) 
was established between urinary specific gravity and GHB 
concentration, although making corrections for urine dilution 
is probably not necessary.  
 Because of the large sample size this study provides 
useful information and supports use of a cut-off between  
5 mg/L and 10 mg/L to distinguish endogenous levels  
from exogenous intake of GHB in living subjects. The 
corresponding cut-off concentration for GHB analyzed in 
venous blood samples is lower and many laboratories 
endorse a level of 3-5 mg/L, because fresh blood show very 
low GHB levels (<0.5 mg/L). In another study of 50 urine 
samples from normal healthy women, the highest concentration 
of endogenous GHB was 1.46 mg/L and the authors 
considered 5 mg/L as a suitable cut-off concentration for use 
in forensic casework [137]. 
 Analysis of alcoholic and nonalcoholic beverages found 
they contained small amounts of GHB, although these lack 
forensic significance because of massive dilution that occurs 
with total body water after drinking usually amounts [145]. 
The endogenous concentrations of GHB in urine did not 
depend on the person’s gender, smoking or alcohol drinking 
habits and concentrations in most people were < 10 mg/L /L 
[146]. Urinary GHB concentrations in people suffering from 
diabetes (N = 20) ranged from 0.17-3.03 mg/L compared 
with 0.16-2.14 mg/L in healthy control individuals (N = 30). 
In pregnancy mean GHB, GBL and BD in urine were 0.36, 
0.34 and 1.92 mg/L compared with 0.24, 0.08 and 0.40 mg/L 
in non-pregnant women [147]. The general consensus is that 
a practical and robust urinary cut-off concentration for GHB 
is 5-10 mg/L for clinical and forensic purposes when 
samples are from living individuals [142].  
 GHB concentrations were determined in N = 100 
forensic urine preserved with sodium fluoride (1%) when no 
evidence suggested intake of exogenous GHB. After storage 
at room temperature for 1 year, the mean and median 
concentrations of GHB were 1.8 mg/L and 1.6 mg/L, 
respectively, although some individual reached 7 mg/L. 
More than 95% of urine samples stored at room temperature 
for 12 months contained less than 5 mg/L GHB and 100% 
were less than 10 mg/L. These results also supports the use 
of an administrative cutoff concentration of 10 mg/L for 
routine analysis of GHB in ante-mortem urine samples 
[148].  
 Urine samples from N = 207 people who claimed no 
prior intake of GHB were analyzed in duplicate by a GC-MS 
method [140]. The urinary GHB concentrations ranged from 
0 to 2.70 mg/L with a median concentration of 0.24 mg/L. 
The average GHB concentration in male donors (n = 130) 
was 0.27 mg/L (range 0-2.70 mg/L), compared with 0.29 mg/L 
(range 0-0.98 mg/L) from females (n = 77); no significant 
gender difference. 
 In 55 healthy people aged from 6-59 y, the median 
concentration of GHB in urine was 1.3 mg/L (mean 1.65 
mg/L and range 0.9-3.5 mg/L), further supporting use of a 10 
mg/L cut-off concentration in forensic toxicology casework 
[141].  
 Oral fluid (saliva) also contains measurable amounts of 
endogenous GHB at roughly the same concentrations as in 
urine. In 120 individuals, the mean, median and range of 
GHB concentrations in mixed saliva were 1.29 mg/L, 1,13 
mg/L and 0.15-3.33 mg/L [75].  
DRIVING UNDER THE INFLUENCE OF GHB  
 GHB is a common recreational drug of abuse in many 
countries and accordingly is often encountered when blood 
and urine samples are analyzed from people arrested by the 
police for DUID. In this connection, it is important to 
consider that between 30-120 min usually elapses after the 
time of arrest until time of drawing blood for toxicological 
analysis. During this time appreciable amounts of GHB are 
removed from the body by metabolism in the liver so the 
concentration reported are probably a lot less than existed at 
the time of driving.  
 The very short elimination half-life of GHB and rapid 
metabolism might be used to argue that it is more correct  
for legal purposes to make a back-estimation of GHB 
concentration as is sometimes done for blood-ethanol. 
However, to the best of our knowledge back calculation of 
GHB concentrations in blood to the time of driving has never 
been done in criminal cases. 
 Table 6 compares the concentrations of GHB in blood  
of apprehended drivers in Sweden and results are shown 
when GHB was the only psychoactive substance detected  
and when other drugs were present in blood samples. Poly-
drug use is common among apprehended drivers in most 
nations and can have considerable influence on drug-induced 
impairment and risk of involvement in a traffic crash.  
The median concentration of GHB of DUID suspects in 
Sweden (81 and 83 mg/L) were similar to drivers arrested in 
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Washington State [149] and in Norway [63]. Abuse of GHB 
by drivers in Germany was less prevalent, although the 
laboratory strategy usually dictates that GHB is analyzed 
when all other drugs are negative [150].  
 The average age of motorists arrested in Sweden  
with GHB in blood was 23-25 y and there was a clear 
predominance of males (Table 6). The proportion of female 
users of GHB was higher among those arrested for petty drug 
offences and also in fatalities after overdosing with GHB.  
POST-MORTEM CONCENTRATIONS OF GHB  
 The endogenous concentrations of GHB are higher in 
blood and urine samples collected during autopsies 
compared with specimens from living people. According to a 
Japanese study, one of the mechanisms accounting for 
biosynthesis of GHB after death is the foul smelling 
substance putrecine (tetramethylenediamine) derived from 
decaying animal tissues. This diamine molecule is the 
product of protein breakdown after death and gets converted 
into 4-amino-butylaldehyde [151]. Further oxidation  
yields GABA and via succinic semialdehyde GHB can be 
generated. The concentrations of GHB in blood from charred 
bodies were lower than in non-burnt corpses and the authors 
suggested that heat degeneration of enzyme protein might 
have prevented the synthesis of GHB in the early post-
mortem period [151].  
 Because of the wide variation in endogenous GHB 
concentrations in post-mortem blood and urine higher cut-off 
concentrations are needed to differentiate ante-mortem 
ingestion from post-mortem production of GHB. The 
proposed thresholds from different investigations and from 
different countries are 20 mg/L in urine and 30-50 mg/L in 
blood samples [46, 47].  
 An early report by Elliot [152] determined GHB in 13 
cadavers and mean concentration in blood was 57 mg/L 
(range 0-197 mg/L) and mean in urine was 56 mg/L (range 
0-217 mg/L). These results were challenged as being 
unusually high and because information about cause or 
manner of death and condition of the bodies was lacking, 
and post-mortem interval and use of fluoride preservative 
was not mentioned [153]. This prompted a follow-up study 
by Elliot [47] and he now reported a mean endogenous GHB 
concentration 12.3 mg/L (range 2-29 mg/L, N = 38) in non-
preserved blood compared with 12.6 mg/L (range 4-25 
mg/L, N = 17) with fluoride.  
 Concentrations of GHB in post-mortem urine samples 
were lower than in blood averaging 5.5 mg/L (range 0-18 
mg/L, N = 39) without fluoride and 4.8 mg/L (range 0-10 
mg/L, N = 15) with fluoride. Others have verified that urine 
is less susceptible to post-mortem synthesis of GHB and this 
is the reason for lower threshold concentrations in this bio-
fluid. Most investigators also recommend addition 1-2% 
fluoride to improve stability of GHB during transport and 
storage [154].  
 The axiom in post-mortem toxicology “an analytical 
results should not be interpreted in isolation” certainly rings 
true when it comes to interpreting GHB concentrations. The 
entire case scenario should be considered, including 
demographics of the deceased, circumstances surrounding 
the death, findings at the scene, police reports, the person’s 
medical records and whether any life-saving treatment was 
given. Furthermore, much can be gained by analysis of GHB in 
specimens collected from different anatomical sites (blood, 
urine, CSF or vitreous humor). Finding concentrations above 
the reporting thresholds in several or all specimens analyzed 
speaks strongly towards ante-mortem ingestion of an illicit 
drug [78].  
 The blood samples submitted for analysis in post-mortem 
toxicology should if possible be taken from a peripheral 
(femoral) vein after clamping proximally to avoid drawing in 
blood from the central compartment. The GHB cut-off 
concentration for reporting positive results in death 
investigations are 30 mg/L for femoral blood and 50 mg/L 
for heart blood [78].  
 Table 7 summarizes the results of a recent study of GHB 
concentration in blood and urine in relation to post-mortem 
interval and temperature of storage. GHB was analyzed by a 
LC-MS method before and after storage of specimens at 4oC 
for 4 months without any fluoride preservative added. The 
endogenous concentrations of GHB increased with post-
mortem interval and also with time of storage, but were  
still less than the established and recommended cut-off 
concentrations of 20 mg/L for urine and 30 mg/L for blood 
off [155]. 
 The concentrations of GHB were determined in various 
body specimens taken from a verified overdose death [77]. A 
targeted analysis revealed GHB in urine, brain, vitreous 
fluid, femoral blood, heart blood, and liver at concentrations 
of 1665 mg/L, 102 mg/kg, 48 mg/L, 461 mg/L, 276 mg/L, 
Table 6. Age, gender and concentrations of GHB in blood in three forensic toxicology materials including, impaired drivers, 
people arrested for abuse of drugs (non-traffic cases) and GHB related deaths [19, 20, 64]. 
Forensic Blood Samples from  N Gender, N (%)  
Men            Women  
Age, y (Mean ± SD)  
Men                Women  
GHB Conc. mg/L  
Mean (Median) Highest  
Impaired drivers, GHB only drug 215 209 (97) 6 (3) 25 ± 4.9 33 ± 6.2 91 (83) 270 
Impaired drivers, GHB + other drugs 333 314 (94) 19 (6) 26 ± 5.1 32 ± 7.2 88 (81) 340 
Users of illicit drugs (non-traffic) 1061 935 (88) 122 (12) 25 ± 5.4 23 ± 6.5  118 (110) 840 
Post-mortem, GHB-related deaths  37 30 (81) 7 (19) 27 ± 7.4 21 ± 5.0 249 (190) 2200 
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and 52 mg/kg, respectively. The confirmation of GHB in 
urine and vitreous fluid is important in death investigations, 
because the risk of post-mortem synthesis is lower than for 
blood. In another single GHB fatality the concentrations of 
GHB were 330 mg/L in femoral blood and 221 in brain 
tissue from the frontal cortex [156]. 
 Different site-dependent production of GHB was verified 
in a study of 25 corpses and short post-mortem interval of 
only 2 days [78]. The mean concentrations of endogenous 
GHB in femoral blood, cerebrospinal fluid (CSF), vitreous 
humor, bile, and urine were 4.6 ± 3.4 mg/L, 1.8 ± 1.5 mg/L, 
0.9 ± 1.7 mg/L and 1.0 ± 1.1 mg/L, respectively. These 
findings led to the suggestion of using cut-off concentrations 
to discriminate between exogenous and endogenous GHB  
of 30 mg/L for blood and 10 mg/L for urine in death 
investigations and in bodies without any decomposition [78]. 
Kintz et al [44] recommended a 50 mg/L GHB cut-off 
concentration if the drug is analyzed in heart blood in order 
to discriminate between endogenous production and ante-
mortem ingestion.  
 Table 8 presents the analytical toxicology results from 
investigations of GHB intoxication deaths in Sweden and 
shows the age and gender of the victims and other relevant 
drug-use information. The toxicity of GHB is enhanced if 
taken together with other CNS depressants and relatively 
high concentrations of ethanol were reported in several of 
these cases. 
 An appreciable overlap exists between GHB 
concentrations in femoral blood in intoxication deaths and 
other causes of death and also between living cases (DUID 
suspects) and autopsy cases [5, 6]. This means that blood 
concentration alone is not sufficient to state that a person 
died of GHB intoxication [20]. The average concentration of 
GHB in autopsy blood in 10 deaths in Australia was 231 
mg/L and the range was 77-370 mg/L [4], which compares 
well with a mean and median concentration of 190 mg/L and 
294 mg/L in 37 deaths reported from Sweden [20].  
 By far the largest case series of GHB-associated deaths 
was compiled by Zvosec et al [21] and details were 
presented of 226 fatalities. Most victims (N = 213) died from 
cardiopulmonary arrest before arrival at hospital for life-
saving treatment and 13 deaths were the results of some type 
of accident. Without any co-ingested drugs the median GHB 
concentration in post-mortem blood was 347 mg/L and the 
range was from 18-4400 mg/L, although the source of blood 
whether central or peripheral was not stated. The same 
authors identified three deaths associated with use and/or 
abuse of Xyrem® [14]. 
ACUTE GHB INTOXICATION 
Clinical Presentation 
 The clinical presentation of GHB intoxication depends on 
the dose, the route of administration and individual tolerance 
to depressant drugs. Treatment of poisoned patients represents 
Table 7. Effect of post-mortem interval on endogenous concentrations of GHB in femoral blood and urine before and after storage 
of specimens at 4 °C for four weeks.  
Post-Mortem Interval, h	   N	   Blood GHB, mg/L (Mean ± SD)	  
Autopsy                          4 Weeks at 4oC	  
Urinary GHB, mg/L (Mean ± SD)	  
	  	  	  	  	  	  	  	  	  Autopsy                       4 Weeks at 4oC 	  
24-36	   10	   2.1 ± 1.1	   2.3 ± 1.1	   3.9 ± 1.7	   4.2 ± 1.9	  
37-72	   10	   5.1 ± 2.8	   5.6 ± 2.8	   3.9 ± 2.6	   4.2 ± 2.6	  
73-192	   10	   11.8 ± 5.5	   13.0 ± 5.6	   9.8 ± 5.1	   11.1 ± 5.2	  
 
Table 8. Analytical toxicology findings in GHB-related intoxication deaths shown in decreasing order of the concentrations in 
femoral blood. More information about these GHB-related deaths is available as electronic supplementary material in 
reference [20].  
Case Age, y  
(Gender) M/F 
GHB in  
Blood, mg/L 
GHB in  
Urine mg/L 
Other Relevant Toxicology Findings 
1 24 (F) 390 1700 Ethanol negative in blood, flunitrazepam + metabolite, tramadol, and amphetamine positive. 
2 20 (M) 260 4600 Ethanol negative in blood, flunitrazepam + metabolite positive. 
3 32 (M) 210 1700 Ethanol negative in blood, morphine (heroin), codeine amphetamine benzoylecgonine,  
THC and citalopram positive.  
4 21 (M) 190 2300 Ethanol negative in blood, diazepam, nordiazepam and propiomazine + metabolite positive. 
5 15 (M) 180 3000 Blood ethanol 1.0 g/L, urine ethanol 1.3 g/L. 
6 31 (M) 170 300 Blood ethanol 1.7 g/L, urine ethanol 2.5 g/L, nordiazepam positive in blood 
7 30 (F) 140 620 Blood ethanol 1.6 g/L, urine ethanol 2.0 g/L, fenfluramine + metabolite positive in blood 
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a medical challenge because the signs and symptoms are 
nonspecific and might be confused with gross ethanol 
intoxication or intake of other sedative-hypnotic drugs such 
as barbiturates or benzodiazepines.  
 The typical signs and symptoms associated with acute 
GHB intoxication are presented in Table 9 as was observed 
and documented in people admitted to hospital for treatment 
of GHB intoxication and recorded by the police in 
connection with arresting impaired drivers or users of illicit 
drugs. 
 The clinical course of GHB intoxication was studied in 
88 patients (61 males and 27 female, mean age 28 years) 
admitted for treatment [157]. As many as 67% of patients  
(N = 59) had co-ingested other drugs, mainly alcohol  
(39% of cases), and second lace was amphetamines (28%). 
The Glasgow Coma Scale (GCS) in 53 subjects was lower 
than 9 (25 patients had GCS score = 3; 28 had a score from  
4 to 8). Most patients regained consciousness spontaneously 
within 5 hours after they were admitted to hospital. 
 The commonest clinical manifestations of GHB 
intoxication in emergency service patients with GCS less or 
equal to eight were bradycardia and hypotension. Other 
things noted were hypothermia and acute respiratory acidosis 
with tachycardia and hypertension between 15 and 30 min 
post-ingestion.  
 In an investigation of drug emergencies in Spain, 104 
GHB overdose cases were documented (3.1% of all 
toxicological emergencies). The typical patient profile was a 
person aged 23 ± 5.1 y mainly male (64%) and presenting on 
weekends (90%). Poly-drug use is common including 
ethanol (73%) or illicit drugs (86%) or both and 16% of 
those admitted were unconscious with a GCS of 3 [158]. 
Complete recovery occurred without sequelae in all patients. 
Clearly there is a need to consider types of co-ingested  
drugs when GHB overdose patients are treated, because this 
might influence the clinical presentation and severity of 
intoxication.  
 The mean age of patients admitted to a hospital in 
Washington State for overdosing with GHB was 28 y (range 
17-59 y) and the vast majority (83%) were male [159]. The 
mean (median) and range of GHB concentrations in blood 
were 137 mg/L (193 mg/L) and 29-490 mg/L, respectively. 
Other drugs besides GHB were identified in 67% of patients 
particularly ethanol in 41% of patients. Typical signs and 
symptoms of GHB overdose were vomiting, ataxia, no gag 
reflex, respiratory depression, coma and sudden altered states 
of consciousness. Many patients required intubation and on 
regaining consciousness they became combative and needed 
to be restrained. The vast majority were sufficiently alert to 
be discharged 6 h after hospital admission.  
 The first symptoms of GHB intoxication occur within 15-
50 minutes after intake and users feel less inhibited and 
experience a mild euphoria. The gastrointestinal disturbances 
include vomiting in 20-55% of cases, abdominal pain and 
excessive production of saliva (sialorrhea). Rapid recovery is 
the rule when it comes to acute GHB intoxication and this 
fits with the short plasma elimination half-life of this 
sedative drug, although hospital treatment may be necessary 
[160].  
 Seventy-six past users of GHB in Australia were given a 
structured interview to investigate their experiences about 
harmfulness of the drug [161]. A large majority reported 
experiencing adverse effects (99%) at least once with 52% 
becoming unconscious, 53% vomiting, 58% reporting 
profound sweating, and 8% said they had a fit or seizure. 
Clearly GHB use and abuse represents a medical risk for 
many recreational drug users. 
 Accidental exposure to GHB was documented in toddlers 
in the UK, Australia and USA from an unexpected innocent 
source, namely a child’s toy. The children showed signs and 
symptoms of intoxication including depressed consciousness, 
some became non-responsive and comatose, but all showed 
rapid recovery with no long-term neurological consequences. 
Investigations showed that the source of GHB was brightly 
colored beads, which were coated with a glue-based product 
made from BD. The toys were manufactured in China and it 
appears BD had mistakenly been used as solvent for the 
plastic instead of 1,5-pentanediol [162, 163].  
TREATMENT OF GHB INTOXICATION 
 The strategy used to treat people admitted to hospital 
emergency departments intoxicated with GHB/GBL/BD is 
essentially supportive and requires monitoring vital signs 
and ensuring the airways are clear, because emesis is 
common. Physicians should pay particular attention to 
cardiovascular and respiratory symptoms and if the patients 
are unconscious then intubation should be considered for the 
first few hours of recovery. According to different studies 
the prevalence of intubation of GHB poisoned patients varies 
from 10 to 57%, whereas the mean duration of intubation 
ranges from 80 to 210 minutes [157, 164]. 
 Cardiovascular symptoms resulting from overdosing with 
GHB don’t normally require invasive therapy although the 
Table 9. Neurological symptoms related to acute GHB intoxication and overdose. 
Occurrence Symptoms of GHB Intoxication after Oral Ingestion of Intoxicating Doses 
Very often  Relaxation, disinhibition, feelings of inebriation, ataxia, disorientation, dizziness, euphoria, confusion,  
hallucinations, somnolence, slurred speech, nausea, miosis, hypothermia. 
Often  Dysarthria, confusion, headache, incoordination, euphoria, amnesia, hypotonia, hyporeflexia,  
tremor, myoclonus, horizontal and vertical gaze nystagmus. 
Seldom  Bruxism, vertigo, increased sexual arousal, delusions, extrapyramidal side effects, dystonias, athetoid posturing, mydriasis 
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bradycardia might be treated by administration of atropine. 
ECG anomalies are not typical of GHB intoxication and if 
they do occur are probably caused by co-ingestion of other 
drugs [19].  
 Table 10 gives examples of the types of drugs used in 
attempts to reverse the intoxication and sedative effects of 
GHB in emergency department patients and also in various 
animal studies. In one study, physostigmine showed  
some promise in reversing GHB-induced altered states of 
consciousness [165, 166], although its efficacy was later 
challenged [167]. Neither naloxone, a pure opiate antagonist 
[168], nor the selective benzodiazepine receptor antagonist 
flumazenil [169] were effective in reversing GHB sedation. 
A novel GABA-B antagonist was tested in mice as a way of 
lowering mortality caused by massive doses of GHB, but it 
did not seem to have any beneficial effects [170]. Taken 
together, these investigations and the types of drugs used 
have so far not provided a practically useful antidote to treat 
patients heavily intoxicated with GHB.  
GHB WITHDRAWAL SYNDROME 
Clinical Presentation 
 The acute pharmacological effects of GHB and GBL are 
of relatively short duration because of the rapid clearance of 
parent drug from the bloodstream and also the lack of any active 
metabolites. After regular use of increasing doses, the signs 
and symptoms of GHB withdrawal become apparent usually 
within 1-6 hours after taking the last dose. It should be pointed 
out that the clinical course of GHB withdrawal symptoms might 
be fairly long, lasting 14 days or more. After detoxification, 
some patients suffer from continuous anxiety and depression 
with cognitive deficits and persistent insomnia.  
 Table 11 classifies as mild, moderate and severe the most 
common GHB withdrawal symptoms. The most prevalent 
were anxiety, insomnia, tremor, tachycardia, affect liability, 
confusion, paranoia, agitation, delirium and hallucinations 
[171]. Less commonly observed was fever, fatigue, diaphoresis, 
arrhythmias and itching. Other clinical manifestations 
frequently described are confusion, disorientation, hyper- 
tension and paranoia. All these symptoms have an average 
duration between 3 and 21 days.  
 The first symptoms of GHB withdrawal tend to appear 
within 24 hours after the last exposure when people start to 
become nervous and anxious and have difficulties in 
sleeping. Vomiting is common in the early withdrawal 
period. The withdrawal symptomatology changes over the 
following 5 days (from 24 hours to 6 days after last dose) 
with clinical manifestations of anxiety, delirium, confusion, 
insomnia and visual hallucinations being documented. Only 
episodic symptoms (anxiety, confusion, insomnia and visual 
hallucinations) occur from 7 to 15 days after the last dose. 
 Some symptoms of GHB withdrawal, such as delirium, is 
more often encountered after chronic drug use on average 
every 2-3 hours, with a range of 0.5-8 hours, compared with 
less intensive usage on average every 7 hours, with a range 
of 1-24 hours. The clinical presentation of GHB withdrawal 
shares common features with ethanol and/or benzodiazepines 
dependence.  
WITHDRAWAL THERAPY 
 There is overwhelming evidence that long-term abuse  
of GHB and GBL leads to addiction and development of 
tolerance and physical dependence, which means that abrupt 
cessation of intake triggers the withdrawal syndrome [48, 
Table 10. Examples of drugs used in the treatment and reversal of acute GHB intoxication. 
Drug (Trade Name in USA) Class of Medication Limitations/Comments 
Phenytoin (Dilantin®) 
Phenobarbital (Luminal®) 
Anticonvulsant/antiepileptic. No apparent effect on coma induced by GHB. 
Clonazepam (Klonopin®) Diazepam 
(Valium®) 
Lorazepam (Ativan®) 
GABA-A receptor agonists. Effective to treat withdrawal effects of GHB. 
Flumazenil (Anexate®)  GABA-A receptor antagonist. No influence on CNS depression. 
Naloxone (Narcan®) Pure µ-opiate receptor antagonist. No effect on GHB-induced respiratory depression. 
Physostigmine (Antilirium®) Cholinesterase inhibitor and thus a potential antidote 
to reverse effects of anticholinergic agents.  
No major benefit and after GHB overdose and this 
treatment might precipitate seizures or cardiac arrhythmias. 
 
Table 11. Typical symptoms of GHB withdrawal classified as mild, moderate and severe. 
Severity  Typically Observed Symptoms of GHB Withdrawal  
Mild  Anxiety, agitation, sweating, restlessness, insomnia, mild hypertension. 
Moderate  Tremor, tachycardia, nausea, vomiting, abdnominal cramps, diarrhea. 
Severe Tachycardia, hallucinations, delusions and pranoia, delirium, hypertension, rhabdomyolysis, seziures. 
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172, 173]. This requires medical intervention and appropriate 
in-patient treatment at a hospital or a psychiatric facility, 
because the seizures that develop might be life-threatening, 
as they sometimes are during ethanol withdrawal [174].  
 The signs and symptoms of GHB withdrawal vary from 
patient to patient depending on extent and duration of prior 
drug exposure [175-178]. Based on numerous clinical reports 
and case studies in the medical literature some general 
guidelines are available. However, there is no official evidence-
based treatment protocol for use during withdrawal from 
GHB and/or its analogues [171, 179, 180]. 
 The best proven therapy seems to be administration  
of high-doses of certain benzodiazepines (e.g. diazepam, 
lorazepam) for 1-7 days depending on the severity of 
withdrawal symptoms [181-183]. When benzodiazepine 
administration alone is not effective, co-medication, 
including the use of anticonvulsants such as barbiturates, or 
the newer GABA-B receptor agonist baclofen or even an 
antipsychotic, such as olanzapin might be indicated [184].  
 Abrupt withdrawal from long-term abuse of GHB 
represents a medical emergency requiring an intervention 
from specialists in addiction medicine and psychiatric 
rehabilitation is motivated because very often the patient 
abuses several drugs, not only GHB [178]. Depending on the 
frequency of intake of GHB or the total daily dose consumed 
an algorithm was proposed for best possible treatment 
outcome [180]. For those taking three or more doses of GHB 
per day or more than 30 g of GHB in 24 hours, the 
administration of diazepam (80-150 mg) daily for up to 7 
days is recommended. If delirium is present the dose of 
diazepam should be raised and if symptomatology persists 
for more than 24 hours, administration of pentobarbital 
might be considered [184].  
 The withdrawal protocol suggested by McDonough et al 
[180] depends on duration of GHB abuse and amounts of 
drug normally taken per day. In less severe cases (<3 doses 
per day) or <30 g of GHB in 24 hours, lower doses of 
diazepam (20-40 mg) should be administered for up to 7 
days (Table 12). 
CONCLUDING REMARKS  
 Reliable information about the popularity and extent of 
GHB use as a recreational drug in various countries around 
the world and its diffusion (including GHB precursors) in the 
general population is not easy to find in the literature. 
Nevertheless, the abuse of GHB continues to unfold as 
evidenced by hospital admissions for treatment of poisoned 
patients’ and forensic toxicology casework as well as scores 
of publications in the medical and toxicology literature. Use 
of GHB is dangerous when skilled tasks, such as driving, are 
performed and many traffic offenders have GHB in blood or 
are involved in road-traffic crashes [19].  
 Evidence that GHB or its analogues are used in cases of 
DFSA is difficult to obtain, owing to the time that elapses 
after the crime is committed before body fluids are taken for 
toxicological analysis. In recent surveys of DFSA cases  
in the Netherlands and Canada, forensic evidence for 
involvement of GHB was available in only 2% of cases  
[185, 186]. Another large review of drug-facilitated crimes 
implicated GHB in 0.2-4.4% of cases, being much lower than 
involvement of other incapacitating drugs, such as ethanol 
[57, 187]. This rapid clearance of GHB from blood after 
ingestion means that concentrations return to endogenous 
levels within 4-6 h after intake [49]. The analysis of GHB in 
hair strands offers an alternative specimen to verify a single 
exposure to GHB [102]. But care is needed to avoid external 
contamination of the hair and special washing procedures 
and cut-off concentrations are necessary to differentiate 
passive exposure from exogenous intake.  
 Treatment of acute GHB intoxication represents a 
medical challenge because symptoms are nonspecific and 
can be confused with intoxication caused by other CNS 
depressants, such as ethanol and/or benzodiazepines. The 
clinical features of GHB intoxication resemble over-
consumption of alcohol excitement, agitation, sleepiness and 
unconsciousness depending on the dose. The oft reported 
cardiovascular disturbances include bradycardia and 
hypotension and respiratory failure and circulatory collapse 
occur after massive doses. The therapy is essentially 
supportive including monitoring of vital signs and ensuring 
no aspiration of stomach contents when in an unconscious or 
comatose state the person vomits.  
 Some emergency physicians advocate endotracheal 
intubation of comatose patients to protect against aspiration 
and gastric insufflations. Use of activated charcoal or gastric 
lavage is unlikely to help matters because GHB is absorbed 
very rapidly after oral administration reaching peak plasma 
concentrations in 20-40 min. Moreover, intoxicated patients 
mostly present for treatment late and at a time when the  
drug is fully absorbed and distributed in all body fluids. 
Moreover, gastrointestinal decontamination itself might 
induce vomiting, and heighten the risk for aspiration 
pneumonia.  
 The rapid clearance of GHB compared with other poisons, 
such as methanol and ethylene glycol, also means that 
invasive treatments, such as hemodialysis or hemofiltration, 
Table 12. Therapeutic approaches involving treatment with high doses of benzodiazepines for GHB withdrawal. 
Study (Reference) Year  Drug Therapy Given Duration of Treatment  
Craig et al [198] 2000 507 mg of lorazepam 
120 mg of diazepam 
Over 90 hours 
Chin [199] 2001 1,138 mg of lorazepam Over 4 days 
Dyer et al [179] 2001 129 mg of lorazepam  During the first day of withdrawal  
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are hardly beneficial [188]. Treatment with the alcohol 
dehydrogenase inhibitor formepizole (4-methyl pyrazole) 
was suggested when people ingested 1.4-butanediol (BD) 
solvent as an alternative to GHB [189]. But whether  
this treatment actually influenced the clinical course of 
intoxication is doubtful considering the very rapid conversion 
of BD into GHB (see Fig. 7).  
 The clinical presentation of GHB intoxication and 
withdrawal shows common features with alcohol and/or 
benzodiazepine abuse, although the mechanism of active is 
different [175]. Making a differential diagnosis between 
GHB and ethanol intoxication often rests on the results of 
toxicological screening analysis. Although there is no 
official detoxification protocol for GHB withdrawal the most 
widely used treatment is to give high doses of benzodiazepines 
(lorazepam or diazepam) for the first few days after 
admission. Depending on response, this medication might be 
supplemented with barbiturates or antipsychotics.  
 GHB is an endogenous substance and low concentrations 
are present in blood and urine from healthy individuals never 
exposed to GHB or its congeners. These so-called “normal” 
GHB concentrations are usually less than 2 mg/L in urine 
and barely measurable in venous blood samples (<0.5 mg/L), 
although occasional higher concentrations in urine < 5 mg/L 
have been reported. Much depends on temperature and 
duration of storage of the specimens and whether a fluoride 
preservative was added. The in-vitro production of GHB is 
more of a problem when dealing with specimens taken from 
corpses as in post-mortem toxicology. This makes it 
imperative to use conservative cut-off limits before a person 
is accused of taking an illicit drug, such as GHB, or when 
bereaved relatives or next of kin are told that results of post-
mortem toxicology were indicative of ante-mortem intake of 
GHB. 
 The usual analytical cut-off concentrations of GHB in 
living subjects are 3-5 mg/L for blood and 5-10 mg/L for 
urine and higher results point towards exogenous exposure to 
GHB. For post-mortem specimens the corresponding GHB 
concentrations are 30 mg/L for femoral blood and 30 mg/L 
for bladder urine are usually recommended. Moreover, all 
the circumstances surrounding the death need to be 
considered, including condition of the body (post-mortem 
interval), extent of trauma and any decomposition, discovery 
at the scene of death, age, gender and occupation of the 
deceased and prior medical history. The stability of GHB is 
improved by keeping the specimens in a refrigerator or 
frozen and sodium fluoride (1-2 %) should be added as 
enzyme inhibitor to help stabilize GHB concentrations. 
 Use of sodium oxybate medication as a treatment for 
alcohol withdrawal has a 20-year history in some countries, 
such as Italy. There is good evidence that GHB taken several 
times daily helps to reduce craving and prevent relapse to 
drinking alcohol [190]. The most effective pharmacotherapy 
for alcohol withdrawal is an open question, although 
available evidence suggests that GHB is just as effective as 
naltrexone or acamprosate [37, 191]. To our knowledge there 
does not appear to be any diversion of sodium oxybate 
(GHB) from the licit to illicit market as has happened on 
such a large scale with other medications subject to abuse, 
such as methadone and oxycodone [192] both widely used 
for pain management [192, 193]. 
 Although the newer “club drugs” or “legal highs” such  
as spice (synthetic cannabinoids) and bath salts (synthetic 
catinones), currently attract a lot of attention from the news 
media and many publications in the medical and forensic 
literature [194-197], GHB and its analogues continue to 
represent a public health problem and are commonly 
encountered in DUID investigations and in post-mortem 
toxicology when poisoning deaths are investigated [7, 8]. 
Forensic practitioners need to appreciate the difficulties in 
interpreting GHB concentrations and be able to differentiate 
post-mortem synthesis from ante-mortem ingestion of this 
illicit drug.  
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